Brought to you by 
TPG-Axon provides Eli Lilly with funds for Alzheimer's trials
21 Aug 2012
Executive Summary
Investment firm TPG-Axon Capital has provided Eli Lilly with more than $300mm in funding to put towards clinical trials for two of the company's late-stage Alzheimer's disease candidates.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Special-Purpose Financing Vehicle
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TPG-Axon provides Eli Lilly with funds for Alzheimer's trials
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice